Keyphrases
Cardiovascular Outcomes
100%
Type 2 Diabetes Mellitus (T2DM)
60%
BMI Variation
54%
Meta-analysis
49%
Precision Medicine
45%
Type 2 Diabetes Prevention
43%
GLP-1 Receptor Agonist
43%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
43%
Heterogeneous Treatment Effects
43%
Clinical Translation
43%
Weight Variability
43%
Second International
43%
International Consensus
43%
Consensus Document
43%
Relative Risk
43%
Precision Diabetes
43%
Systematic Meta-analysis
43%
Real Environment
43%
Clinical Trials
43%
Cardiovascular Risk
34%
Diabetes
32%
Body Weight Variability
27%
Confidence Interval
27%
Clinical Implementation
21%
Clinically Significant
17%
Cardiovascular Mortality
17%
Biological Characteristics
12%
Agonist Treatment
12%
Glycemic Response
12%
Randomized Controlled Trial
12%
Methodological Limitations
12%
Renal Outcome
12%
Clinical Features
12%
REWIND
12%
Bioresources
12%
HbA1c Variability
12%
Tayside
12%
Clinical Preparedness
10%
Decision Recommendation
10%
Precision Medicine Research
10%
Health Recommendations
10%
Systematic Evidence Review
10%
Etiology
10%
Complication Risk
10%
Myocardial Infarction
10%
Reduced Error
10%
Clinical Prognosis
10%
Diabetes Status
10%
Cost-effectiveness
10%
Life-threatening Complications
10%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
87%
Cardiovascular System
56%
Receptor
43%
Systematic Review
43%
Sodium Glucose Cotransporter 2 Inhibitor
43%
Medicine
43%
Diabetes
43%
Treatment Effect
43%
Body Mass Index
43%
Clinical Trial
43%
Personalized Medicine
37%
Glycemic
18%
Observational Study
12%
Randomized Controlled Trial
12%
Meta-Analysis
12%
N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide
10%
Cardiovascular Disease
10%
Hemoglobin A1c
10%
Evidence-Based Medicine
6%
Kidney Function
6%
Post-Hoc Analysis
6%
Cost-Effectiveness Analysis
6%
Combination Therapy
6%
Insulin Release
6%
Medical Decision Making
6%
Cardiovascular Risk
5%
Clinical Study
5%
Apoplexy
5%
Myocardial Infarction
5%
Proportional Hazards Model
5%
Arm
5%
Placebo
5%